InnoCan Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	-1.12	-1.83	-4.7	-3.76	-10.05	Upgrade
Depreciation & Amortization	0.04	0.04	0.03	0.04	0.04	Upgrade
Stock-Based Compensation	1.46	2.01	0.85	0.97	2.16	Upgrade
Other Operating Activities	-1.46	-0.51	0.7	-2.77	2.18	Upgrade
Change in Accounts Receivable	-	0.02	-0	-0.02	0	Upgrade
Change in Inventory	1.14	-1.57	-0.62	-0.62	-0.08	Upgrade
Change in Accounts Payable	0.05	0.07	0.02	0.04	-0.47	Upgrade
Change in Other Net Operating Assets	0.38	0.2	-0.19	0.06	-0.42	Upgrade
Operating Cash Flow	0.5	-1.58	-3.9	-6.07	-6.63	Upgrade
Capital Expenditures	-0.02	-0.02	-0.05	-0.03	-0.04	Upgrade
Other Investing Activities	0	0.07	-0.04	-0.01	-0.01	Upgrade
Investing Cash Flow	-0.02	0.05	-0.08	-0.03	-0.05	Upgrade
Long-Term Debt Issued	0.64	-	-	-	-	Upgrade
Long-Term Debt Repaid	-0.01	-0.02	-0.02	-0.01	-0.04	Upgrade
Net Debt Issued (Repaid)	0.63	-0.02	-0.02	-0.01	-0.04	Upgrade
Issuance of Common Stock	0.09	0.89	1.56	0.14	11.92	Upgrade
Other Financing Activities	0.42	1.84	1.38	-	3.43	Upgrade
Financing Cash Flow	1.15	2.7	2.92	0.13	15.3	Upgrade
Foreign Exchange Rate Adjustments	0.05	-0.06	0.01	-0.13	0.08	Upgrade
Net Cash Flow	1.68	1.12	-1.06	-6.1	8.71	Upgrade
Free Cash Flow	0.48	-1.59	-3.95	-6.09	-6.67	Upgrade
Free Cash Flow Margin	1.80%	-5.42%	-28.92%	-238.10%	-3403.06%	Upgrade
Free Cash Flow Per Share	0.11	-0.37	-1.00	-1.59	-1.93	Upgrade
Cash Income Tax Paid	1.3	1.1	-	-	-	Upgrade
Levered Free Cash Flow	0.22	-0.22	-0.72	-6.25	-7.41	Upgrade
Unlevered Free Cash Flow	0.23	-0.22	-0.72	-6.24	-7.4	Upgrade
Change in Working Capital	1.57	-1.28	-0.79	-0.53	-0.97	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.